REporting recommendations for tumor MARKer prognostic studies (REMARK)

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Nature Clinical Practice Oncology

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ncponc0252PMID 16106022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.

  2007cited by this paper
• Why do so many prognostic factors fail to pan out?

  2005cited by this paper
• Prognostic Factor Studies

  2005cited by this paper
• Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.

  2004cited by this paper
• A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma

  2004cited by this paper
• Methodological challenges in the evaluation of prognostic factors in breast cancer

  2004cited by this paper
• Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines

  2004cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

  2003cited by this paper
• The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

  2003cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative

  2003cited by this paper
• Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future

  2003cited by this paper
• Evaluating Prognostic Factor Studies

  2003cited by this paper
• Biostatistics and tumor marker studies in breast cancer: design, analysis and interpretation issues.

  2003cited by this paper
• A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family.

  2003cited by this paper
• The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration

  2003cited by this paper
• Statistical Methods for the Analysis of Prognostic Factor Studies

  2003cited by this paper
• Introduction: Tumor markers as clinical cancer tests—are we there yet?

  2002cited by this paper
• Prognostic factors in non-small cell lung cancer: a decade of progress.

  2002cited by this paper
• Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies.

  2002cited by this paper
• Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

  2002cited by this paper
• Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years

  2002cited by this paper
• Issues and barriers to development of clinically useful tumor markers: a development pathway proposal.

  2002cited by this paper
• Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

  2002cited by this paper
• Tumor markers as clinical cancer tests--are we there yet?

  2002cited by this paper
• Systematic reviews in health care : meta-analysis in context

  2001cited by this paper
• The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration

  2001cited by this paper
• Systematic reviews of evaluations of prognostic variables

  2001cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

  2001cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

  2001cited by this paper
• 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

  2001cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

  2001cited by this paper
• Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.

  2000cited by this paper
• Reproducibility of p53 Immunohistochemistry in Bladder Tumors

  2000cited by this paper
• Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network.

  2000cited by this paper
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• Meta-analysis of observational studies in epidemiology - A proposal for reporting

  2000cited by this paper
• Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

  1999cited by this paper
• Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.

  1999cited by this paper
• Predicting the future: a critical appraisal of cancer prognosis studies

  1999cited by this paper
• Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

  1999cited by this paper
• A Guide for Reviewing Submitted Manuscripts: (And Indications for the Design of Translational Research Studies on Biomarkers)

  1999cited by this paper
• Prognostic variables in node-negative and node-positive breast cancer

  1998cited by this paper
• Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

  1996cited by this paper
• Review of survival analyses published in cancer journals.

  1995cited by this paper
• Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.

  1994cited by this paper
• Statistical aspects of prognostic factor studies in oncology.

  1994cited by this paper
• The Risk of Determining Risk with Multivariable Models

  1993cited by this paper
• Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients.

  1993cited by this paper
• Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,”

  1993cited by this paper
• Criteria for prognostic factors and for an enhanced prognostic system

  1993cited by this paper
• The future of prognostic factors in outcome prediction for patients with cancer

  1992cited by this paper
• Breast cancer prognostic factors: evaluation guidelines.

  1991cited by this paper
• A Decade of Progress

  1972cited by this paper

• Single-cell RNA sequencing and spatial transcriptomics reveal heterogeneity and key subgroups in ovarian cancer: HOXA1 identified as a potential therapeutic biomarker.

  2026cites this paper
• RNA-Seq Analysis of Nintedanib Effects on Interstitial Pneumonia in Preoperative NSCLC Patients.

  2026cites this paper
• Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

  2026cites this paper
• Multi-omics integrative analysis of stemness-associated pathological signatures to guide prognosis and therapeutic strategies in uveal melanoma.

  2026cites this paper
• CD3+RUNX3+ lymphocyte density; an independent prognostic factor in colon and lung adenocarcinoma but not in lung squamous cell carcinoma

  2026cites this paper
• AIM2 inflammasome and pyroptosis biomarkers in oncology.

  2026cites this paper
• GCN5-ERK lactylation-phosphorylation loop amplifies lactate-driven cancer progression.

  2026cites this paper
• Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancer

  2026cites this paper
• Circulating Micrornas As Prognostic Biomarkers In Pediatric Hematologic Malignancies: A Systematic Review And Meta-Analysis

  2026cites this paper
• Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4

  2026cites this paper
• Prognostic significance of diagnosis-to-surgery interval in oral cavity squamous cell carcinoma: A nationwide study.

  2025cites this paper
• The making of a statistician: Doug Altman

  2025cites this paper
• HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas

  2025cites this paper
• Molecularly redefining small bowel adenocarcinoma to accelerate precision patient care – protocol of a multicenter observational cohort biomarker study

  2025cites this paper
• Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis

  2025cites this paper
• Clinicopathological Significance of Transcription Factor p73 in Breast Cancers: Protein Expression and Transcriptomic Study

  2025cites this paper
• Validation of fibroblast activation protein and α‐smooth muscle actin as prognostic biomarkers in prostate cancer through AI‐assisted image analysis of dual‐marker IHC

  2025cites this paper
• Associations of serum and tissue TIMP1 with host response and survival in colorectal cancer

  2025cites this paper
• Radiomics-based Machine Learning Approach to Predict Chemotherapy Responses in Colorectal Liver Metastases

  2025cites this paper
• The Prognostic Role of miR-375 in Head and Neck Squamous Cell Carcinoma: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis

  2025cites this paper
• The Prognostic Significance of PD‐L1 Expression and Associated Tumor‐Infiltrating Lymphocytes in Supraglottic Laryngeal Squamous Cell Carcinoma

  2025cites this paper
• Lymphovascular Invasion Detection in Breast Cancer Using Deep Learning

  2025cites this paper
• Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer

  2025cites this paper
• Predicting NRAS gene status in colorectal cancer using computed tomography (CT)-based radiomics.

  2025cites this paper
• Characteristics of KRAS WT pancreatic adenocarcinomas: results of a large French multicentric cohort

  2025cites this paper
• Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease.

  2025cites this paper
• Gamma entrainment induced by deep brain stimulation as a biomarker for motor improvement with neuromodulation

  2025cites this paper
• Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate Cancer

  2025cites this paper
• The prognostic value of p53 and Ki-67 expression status in penile cancer: a systematic review and meta-analysis.

  2025cites this paper
• hUC-MSC preserves erectile function by restoring mitochondrial mass of penile smooth muscle cells in a rat model of cavernous nerve injury via SIRT1/PGC-1a/TFAM signaling

  2025cites this paper
• Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer

  2025cites this paper
• Prognostic value of tumor-infiltrating lymphocytes in irradiated node-positive breast cancer patients

  2025cites this paper
• Tumour and normal tissue radiosensitivity: 2025 update.

  2025cites this paper
• Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

  2025cites this paper
• CEACAM7 Expression and DNA Methylation: Prognostic Biomarkers for Lung Adenocarcinoma in African Americans.

  2025cites this paper
• PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling

  2025cites this paper
• Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

  2025influential citation
• Evaluation of changes in prediction modelling in biomedicine using systematic reviews

  2025cites this paper
• Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy

  2025cites this paper
• Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial

  2025cites this paper
• Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)

  2025cites this paper
• Limited research investigating the value of MRI in predicting future cognitive morbidity in survivors of paediatric brain tumours: A systematic-review and call to action for clinical neuroimaging researchers

  2025cites this paper
• High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.

  2025cites this paper
• Ultrasensitive Electrochemical Screening of Circulating Tumor Cells Over Single-Atom Nanozyme Integrated 3D Nanoarray.

  2025cites this paper
• Transcription Factor p73 Is a Predictor of Platinum Resistance and Promotes Aggressive Epithelial Ovarian Cancers

  2025cites this paper
• The prognostic role of HPV status in penile squamous cell carcinoma: a systematic review and meta-analysis

  2025cites this paper
• Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors

  2025cites this paper
• PIAS1 Shapes a Tumor-Suppressive Microenvironment by Suppressing Immune Evasion in Oral Squamous Cell Carcinoma

  2025cites this paper
• CAMSAP3 Suppresses Breast Cancer Metastasis and Serves as an Independent Prognostic Marker

  2025cites this paper
• Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients

  2025cites this paper
• SPOP and MMR/MSI alterations in prostate cancer: relationship with PD-L1, TILs and AR expression

  2025cites this paper
• Construction and validation of a disulfidptosis-related risk assessment model for prediction of prognosis, immune microenvironment, drug therapy and microbiota in patients with low grade glioma.

  2025cites this paper
• Antigen-specific CD8+CD39+ cytotoxic T cell density in the microenvironment of hepatocellular carcinoma predicts patient survival

  2025cites this paper
• Integrative multi-omics identifies endoplasmic reticulum stress-related prognostic biomarkers and CD99-mediated cell-cell communication in lung adenocarcinoma.

  2025cites this paper
• Liver transplantation for intestinal malignancies.

  2025cites this paper
• External validation of plasma CSF1 as a preoperative prognostic marker in patients with resectable intrahepatic cholangiocarcinoma

  2024cites this paper
• Tumor Suppressor miR-27a-5p and Its Significance for Breast Cancer

  2024cites this paper
• An overview about biomarkers in breast cancer: Insights into the diagnostic and prognostic significance.

  2024cites this paper
• A Clinico-Genetic Score Incorporating Disease-Free Intervals and Chromosome 8q Copy Numbers: A Novel Prognostic Marker for Recurrence and Survival Following Liver Resection in Patients with Liver Metastases of Uveal Melanoma

  2024cites this paper
• Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma

  2024cites this paper
• High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC

  2024cites this paper
• Thioredoxin System Protein Expression in Carcinomas of the Pancreas, Distal Bile Duct, and Ampulla in the United Kingdom

  2024cites this paper
• Blood Biomarkers of Long COVID: A Systematic Review

  2024cites this paper
• High Expression of NLR and SII in patients With Nasopharyngeal Carcinoma as Potential Prognostic Observations

  2024cites this paper
• High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome

  2024cites this paper
• ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Oestrogen Receptor-Positive Breast Cancer

  2024cites this paper
• Association of CD133, ALDH1, CD117 and OCT4 expression with prognosis of patients with cervical cancer

  2024cites this paper
• Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression

  2024cites this paper
• Prognostic and predictive implications of sterile alpha motif and HD domain‐containing protein 1 (SAMHD1) expression in breast cancer

  2024cites this paper
• Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion

  2024cites this paper
• Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer

  2024cites this paper
• Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer

  2024cites this paper
• A Systematic Review on Prognostic DNA Methylation Markers for Renal Cell Carcinoma: Are We Moving Forward?

  2024cites this paper
• Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes

  2024cites this paper
• Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors

  2024cites this paper
• Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors

  2024cites this paper
• The Vitamin D Receptor as a Prognostic Marker in Breast Cancer—A Cohort Study

  2024cites this paper
• Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer

  2024cites this paper
• Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer

  2024cites this paper
• Reporting Standards for Complication Studies of Radiation Therapy for Pediatric Cancer: Lessons From PENTEC.

  2024cites this paper
• Restricting datasets to classifiable samples augments discovery of immune disease biomarkers

  2024cites this paper
• Fibroblast Activation Protein-α and the Immune Landscape: Unraveling T1 Non–muscle-invasive Bladder Cancer Progression

  2024cites this paper
• Prognostic significance of the neutrophil to lymphocyte ratio in locally advanced breast cancer

  2024cites this paper
• Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy.

  2024cites this paper
• Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework

  2024cites this paper
• Nonparametric Biomarker Based Treatment Selection With Reproducibility Data

  2024cites this paper
• Advancing Diagnostics and Patient Care: The Role of Biomarkers in Radiology

  2024cites this paper
• Association of the Genetic Diversity of Killer Cell Immunoglobulin-like Receptor Genes and HLA-C Ligand in Saudi Women With Thyroid Cancer

  2024influential citation
• A biopsy-based Immunoscore in patients with treatment-naïve resectable gastric cancer

  2024cites this paper
• Pulmonary metastasectomy for sarcoma: Insights from a referral-center cohort.

  2024cites this paper
• A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer

  2024cites this paper
• Multivariate prognostic index and triplet regimen efficacy predictive index in locally advanced and metastatic gastric cancer: pooled analysis from three clinical trials using individual patient data

  2024cites this paper
• Preoperative glucose-to-lymphocyte ratio predicts survival in cancer

  2024cites this paper
• Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)‐induced phenotypes for platinum sensitivity and long‐term survival in ovarian cancer—A study from the OVCAD consortium

  2024cites this paper
• ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

  2024cites this paper
• Limited Research Investigating the Added Value of MRI in Predicting Future Cognitive Morbidity in Survivors of Paediatric Brain Tumours: A Call to Action for Clinical Neuroimaging Researchers

  2024cites this paper
• CD163+ macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women’s Circle of Health Study and the Women’s Circle of Health Follow-Up Study

  2024cites this paper
• Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy

  2024cites this paper
• Single-cell and spatial transcriptomic analyses reveal heterogeneity characteristics and specific cell subtype regulators in growth hormone-secreting pituitary adenomas.

  2024cites this paper
• Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and Elaboration. Translation into Russian

  2023cites this paper